Using proprietary chemistry technology, the company has created Xerava, a fully synthetic fluorocycline, as an intravenous antibiotic for the treatment of multidrug-resistant bacterial infections, including those found in complicated intra-abdominal infections. Tetraphase is committed to fighting antibiotic resistance, a significant threat to humanity, by developing new antibiotics that can overcome the challenges of drug-resistant bacteria and ensure the availability of effective treatments in the future.